Search

Search Constraints

You searched for: Author/Creator Sho, Takuya

Search Results

11. Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting. Issue 1 (10th June 2019)

12. Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients. Issue 7 (12th April 2022)

13. Effects of resistance‐associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs. Issue 11 (23rd July 2019)

14. Entecavir treatment of hepatitis B virus‐infected patients with severe renal impairment and those on hemodialysis. Issue 11 (25th July 2019)

15. FGFR2 maintains cancer cell differentiation via AKT signaling in esophageal squamous cell carcinoma. Issue 5 (3rd June 2021)

16. Hepatitis B virus X protein impairs α‐interferon signaling via up‐regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A. Issue 2 (3rd August 2016)

17. High serum angiopoietin‐2 level predicts non‐regression of liver stiffness measurement‐based liver fibrosis stage after direct‐acting antiviral therapy for hepatitis C. Issue 6 (18th February 2020)

18. Incidence of post‐transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection. Issue 11 (7th September 2022)

19. Increased serum C‐reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis. Issue 3 (3rd November 2017)

20. Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. Issue 8 (9th July 2020)